全球腺相關病毒（AAV）合約開發和生產組織（CDMO）市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計到 2034 年，AAV 合約開發和生產組織 (CDMO) 市場規模將從 2025 年的 9.3 億美元成長至 40 億美元，2026 年至 2034 年的複合年成長率為 17.61%。

由於對使用腺結合病毒(AAV) 載體的基因療法的需求不斷成長，全球 AAV 合約開發和生產組織 (CDMO) 市場正經歷快速成長。製藥和生物技術公司越來越依賴專業的 CDMO 來開發和生產這些複雜的產品。針對罕見疾病和遺傳疾病的基因治療候選藥物管線的擴展是推動 AAV 生產服務需求的主要因素。

主要成長要素包括企業內部生產的高成本和技術複雜性，促使企業將生產外包給經驗豐富的合約研發生產機構 (CDMO)。病毒載體生產技術的進步和生產設施的擴建也促進了市場成長。基因療法監管核准的增加導致對可靠生產合作夥伴的需求上升。創業投資公司的大力投資和策略合作進一步加速了市場發展。

展望未來，隨著更多基因療法進入商業化階段，市場預計將顯著成長。 CDMO公司正在擴大產能並投資先進技術，以滿足日益成長的需求。可擴展生產流程的持續創新將提高效率並降低生產成本。隨著基因治療產業的成熟，AAV CDMO市場將在支持大規模生產和全球分銷方面發揮關鍵作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球AAV合約開發與生產組織（CDMO）市場：依工作流程分類

• 市場分析、洞察與預測
• 上游工程
• 下游加工

第5章：全球腺相關病毒（AAV）合約開發與生產組織（CDMO）市場：依培養類型分類

• 市場分析、洞察與預測
• 黏附培養
• 懸浮培養

第6章：全球腺相關病毒（AAV）合約開發與生產組織（CDMO）市場：按應用領域分類

• 市場分析、洞察與預測
• 細胞和基因治療開發
• 疫苗研發
• 生物製藥和藥物發現
• 生物醫學研究

第7章：全球腺相關病毒（AAV）合約開發與生產組織（CDMO）市場：按最終用戶分類

• 市場分析、洞察與預測
• 製藥和生物製藥公司
• 學術研究機構

第8章：全球腺相關病毒（AAV）合約開發與生產組織（CDMO）市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Thermo Fisher Scientific Inc
  • Creative Biogene
  • Catalent Inc
  • Charles River Laboratories International Inc
  • Danaher（Aldevron）
  • Forge Biologics
  • Genezen
  • ViroCell Biologics
  • Merck KGaA
  • Viralgen
  • Biovian Oy

The AAV Contract Development And Manufacturing Organizations Market size is expected to reach USD 4.00 Billion in 2034 from USD 0.93 Billion (2025) growing at a CAGR of 17.61% during 2026-2034.

The Global AAV Contract Development And Manufacturing Organizations (CDMO) Market is witnessing rapid growth due to the increasing demand for gene therapies that use adeno-associated virus (AAV) vectors. Pharmaceutical and biotechnology companies often rely on specialized CDMOs to develop and manufacture these complex products. The growing pipeline of gene therapy candidates targeting rare and inherited diseases is significantly driving the need for AAV production services.

Major growth drivers include the high cost and technical complexity of in-house manufacturing, which encourages companies to outsource to experienced CDMOs. Advancements in viral vector production technologies and the expansion of manufacturing facilities are also contributing to market growth. Increased regulatory approvals for gene therapies have created greater demand for reliable manufacturing partners. Strong investment from venture capital firms and strategic collaborations are further accelerating market development.

Looking forward, the market is expected to grow substantially as more gene therapies reach commercialization stages. CDMOs are expanding their production capacities and investing in advanced technologies to meet rising demand. Continuous innovation in scalable manufacturing processes will improve efficiency and reduce production costs. As the gene therapy industry matures, the AAV CDMO market will play a crucial role in supporting large-scale production and global distribution.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Workflow

• Upstream Processing
• Downstream Processing

By Culture Type

• Adherent Culture
• Suspension Culture

By Application

• Cell & Gene Therapy Development
• Vaccine Development
• Biopharmaceutical & Pharmaceutical Discovery
• Biomedical Research

By End-user

• Pharmaceutical & Biopharmaceutical Companies
• Academic & Research Institutes

COMPANIES PROFILED

• Thermo Fisher Scientific Inc, Creative Biogene, Catalent Inc, Charles River Laboratories International Inc, Danaher Aldevron, Forge Biologics, Genezen, ViroCell Biologics, Merck KGaA, Viralgen, Biovian Oy
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: BY WORKFLOW 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Workflow
• 4.2. Upstream Processing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Downstream Processing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: BY CULTURE TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Culture Type
• 5.2. Adherent Culture Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Suspension Culture Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Cell & Gene Therapy Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Vaccine Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Biopharmaceutical & Pharmaceutical Discovery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Biomedical Research Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: BY END-USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-user
• 7.2. Pharmaceutical & Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Workflow
  • 8.2.2 By Culture Type
  • 8.2.3 By Application
  • 8.2.4 By End-user
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Workflow
  • 8.3.2 By Culture Type
  • 8.3.3 By Application
  • 8.3.4 By End-user
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Workflow
  • 8.4.2 By Culture Type
  • 8.4.3 By Application
  • 8.4.4 By End-user
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Workflow
  • 8.5.2 By Culture Type
  • 8.5.3 By Application
  • 8.5.4 By End-user
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Workflow
  • 8.6.2 By Culture Type
  • 8.6.3 By Application
  • 8.6.4 By End-user
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Thermo Fisher Scientific Inc
  • 10.2.2 Creative Biogene
  • 10.2.3 Catalent Inc
  • 10.2.4 Charles River Laboratories International Inc
  • 10.2.5 Danaher (Aldevron)
  • 10.2.6 Forge Biologics
  • 10.2.7 Genezen
  • 10.2.8 ViroCell Biologics
  • 10.2.9 Merck KGaA
  • 10.2.10 Viralgen
  • 10.2.11 Biovian Oy